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Summary and general discussion
SUMMARY
Nhcroalbumrnuria, defined as a urinary albumrn excredon of 30-300 mg per 24 hours,
was first recognised as a risk matker for diabeuc renal disease but it is suggestcd that
microalbuminuria is a marker for renal disease in the generai populauon too. It is
thought to reflect endothelial damage and an earlv sign of atherosclerosis. Indeed,
microalbuminuria appears to be a dsk marker for cardiovascular morbidity and
mortality as well.
'fhis thesis explored thc extent in rvhich drug use could influence urinary
albumin excretion, For this exploration baseline data from the PRE\/END study was
lnked u,rth computerised pharmacy records. Chapter 1 shorvs that the pharmacy data
is <1uite suitable for detecting prescribed drug use. N{ost drug groups we investigated in
this thesis are chronicallv used, e.g. antihwertensi\res, statins, and oral contraceptives.
For these groups we found a good allreement bent".een drug use measured in
pharmacv data and in a .1ue stionnairc. F{owever, the agrecment between
quesrionnaires and pharmacv data is not good for drugs also available ovcr-the-
counter (OTC), because use of thcse drugs is generally not registered in pharmacy
data. Als<i, the agreement is not ve4' good for drugs used "as needed", although
pharmacv data shouid sti l l  be uscful although the data kroses some of its advantages,
like accurate information on duration r>f use.
The frrst wav in which drugs can influence uri.nary albumin excretion is by lowering
the excretion. Two drug classes were investigatcd in this respect, antihlpertensives
and lipid lowering drugs. ln chapter 2 we looked more closely at antihypertensive drug
classes. Recause they lower blood pressure, these drugs may also be able to krwer
urinary albumin excÍetion. Howcver, not all antihlpcrtensives ate equal in their effect
of udnaq. albumin excredon, and tirese differcnces could be independent of the
antihypertensivc properties of these agents. We found a linear relatic>n benveen bkrod
pÍessure and urinarv albumin excretion. However, the slope of this telation was
different fot the various antihvpertensives. Dihyclropyridinc calcium channcl blockers
have a more steep reiation, suglesting these drugs have a less favourabie effect of on
microalbumi.nuria cornpared to other antil'rypertensive drug groups. Interestingly,
ACE, inhibitors did sl"rou' their superioriry in lou,'ering urinary albumin excretion only
when they combined ri'ith a diurctic.
Statins are also suglested to lowcr urinar,,' albumin excretion. In chaptcr 3 wc
investigated the association betrvee n statins and microalbuminuria. Our data could not
confirm our hvpothesis that statins are associated with a lorver prevalence of
microalbuminuria. Statin users with a historv of rnyocardial infarction had a lower, but
non-significant, prevalence of microalbuminuria. However, statin usc as primary
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preventiolr $,rrs i lssoci: l tu. l  rvi th a sh{htl t '  highcr, rathcr than a lo\\ .er, prevalelrce of
nric roalbur-ninurta.
-r\  sccond \\ :av oi drugs inf luencing urir.rart '  albumin excretion is u'hen thcsc cltugs have
nricloalbunrinuLlr ls arr aclvcrsc eftc'ct,  or u, l tcr-t  drugs l-rave carcl iovascr,r lar sidc cFfects,
tor u-hich r-niclral lrr-uninr-Lriu cun bc a markcr. 1n ciraptcr . l  u, ' t '  f l rur-rd that oral
c()ntraccptr\-c r lsrr ancl hormone rcplacemer)t thcrapy arc associatecl u' i th
nricroalbun-rinuria, suggcsLing thut w()Ircn Lrsing thesc drr-rgs havc a higircr
cardiovusctr lar r isk. Ort l  contr2lccpti \res havc ah.va1,5 iree n associatcd l ' i th
c:rrr i lor-uscular r isk, albcit  a srnal l  lbsolutc r isk. T'hese i lncl inl js are in agreen'rent rvi th
thc rrssociurion u' i t l -r  n-r icroalburninr-rr iu rr 'e f i runcl.  Intercst inglt ' ,  u'e founcl a st longer
associat ion ir-r sccc-ind gcnereriorl  oral cotruaccptrvcs c() lnlrreJ u' i th thircl  gcneradon.
' l 'his is rclcr-unt in the clcbatc rvl.rether scconcl gcncration progcstins should be
prcferrecl becur-rsc of t l -rc grcafer r isl i  for vcn()r ls t l rromboen-t i :ol isrn t- i th the third
gcne Íat ion proucstins. i \  los-cr r isk for tnicrol lbturinuria, and possrbly for
at l-rerosclcnrt jc cvcnts u, i th the r-rsc of thircl  gene rat ion oral cr )ntr irccpu\-cs mil \
hou'evcr our\\ 'c igh the grcatcr r iks f<rr ve nous t lrrornbocnrbol isrn u' i t l -r  t l -re sc clrugs.
The rLssociat ion bctu,cen nricroalbr-rnrinuria and holrnonc rcplacement thcÍapr
rvls sonreu,hrt une\pcctccl.  Wc haci expccted to f lncl a bcr-ref lcial effect of holmone
rc;r lucerncnt therapv on thc- r isk fcrr miclralbunl inuria. I  Ios'er-cr, thc re sults of cLinical
tr ials ir-rcl icat ing honlrr,nc rcplaccme nt t l ie r lpv Lrscrs ha\.c an incrcascd cardiovascular
r isk ir-rsteacl of a clecrcascd r isk arc in agrccment \ \ ' i th otrr f incl ings. Tl-re safct l  of
t ibolrn as an altcrnatir-c for convcÍrt ionel h,r11ne11s rcphcemcnt therapv rvas str-rcl icd
in chapter 5. Stmilerlr , ,  t jbolon uras ' .r ls.r associatcd u, i th r l icroalbumir.ruria, ancl in a
cl irc-ct conrparison u' i th conventi()nal irormone lcplacelnel l t  therapv er-en shou'ccl a
i-rigi-rcr isk firl rnicroall rutr-rinuriu.
Ir.r  chapter 6 rve fotrncl microalburninr-rr ia to bc a ; lossiblc aclr,crsc cf icct of
c()rt icoster() icls as l l 'c i l .  Intercst inglv, this ussociut lon u,as preselrt  onlt '  in sr-rbjccts usinu
both slstenric ar-rd krcal cort icostcr-oicls. l t  is known that cort icosteroids har-c a rangc
of carcl iovascular eifects ancl nricrralbunl inlrr ia coukl just bc onc oi thct.n. I  iorvevcr,
ai ier acl just inc t lrr  othcr carcl iovasculur ctfccts, n'r icrt-,albunlnurirt  rvas sri l l  associatcd
u' i th cort icosterr., icl  usc. , \  seconcl explanatlolr is that c()Í t icosteloicls ere used in
st 'r-cral cl iseascs ablc to causc gk.rme nrior-rcphnds. r\ lso, c()rt ic()ste Í() i t ls arc Llsed 1n
inf lan-u-natort diseascs, and int lanrmution ts a possibic causc tbr urinarl '  albun'r in
cxcrct i()n foo. Flou cvcr, basccl on t l-r is stuclï ,  u-c crlnn()t sav i [  anl - or ser.cral - oi
these expl lrnxd()Írs xrc thc reason for thc assc.ici i t t ion bcnvcen cor[costeroicls and
r-r-ricl ralbr-ur-rin r,rria.
ln chaprer 7 u'c cxplored u'hich drr-rgs s'ere associ l ted s' i t l . r  altercd renal function. ln
this or-err- ieu'\ \ 'c lvere ablc to detect cluitc a rrunrber , , i  t l rug gr()uf s to bc rclatccl to un
elevatecl or dir-ninishccl rcnal function. About half  of the se u'ete clrug gr, )uPS thxt \ \ ' (rc
to be expcctcd (such as NSAII)s ancl ar.rt ihvperter.rsir-es), becausc their effcct on the
kiclnu' hacl bcen clcscribccl bcfore. ()thcr dmg gr()ups \\-eÍc Lrncxpccted (such us
prot()n punrp inhibitoÍs, laxati \-es, r 'accincs, and severrr l  cveclrcps) ancl furt l ' rer research
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has to be done to clari.fy whether these drugs were found by chance or really have an
effect on renal function. Interestingly, several of the drugs we found associated with
microalbumi.nuria were also found to be related to h1'perfiltration (e.g. diuretics, oral
contraceptives, and corticosteroids). However, in the PREVEND population
hlperfiltration is associated wrth microalbuminuria, and it is thus not surprising that
we found the same dtug pJroups that were associated with microalbuminuria, also to
be related with glomerular hvperfiltÍation.
DISCUSSION
This thesis looked at drug influences on urinary albumin excretion. For this purpose
we linked computerised pharmacy data with the PREVEND database. This gave us
the opportunity to look at the use of all krnds of drugs, with quite some precision.
Wrth pharmacy data itis possible to investigate not only the use of a drug, but also the
duration of use and the dosage. Thete fore, one of our conclusions is that population
based cohort studies can gain a lot oF detailed information if i t is possible to collect
computerised dispensing data.
The explanations we found fot the different associations between urinary
albumin excretion and drug use roughly fell into rwo categories. The associations werc
either due to a phl,siologic process or due to methodological problems.
Microalbuminuria is an eady marker for atherosclerosis and it shows a
correlation with cardiovascular risk factors like hypertension and dyslipidemia. Drugs
that have cardiovascular effects can thus be associated with microalbuminuria.
Antihvpertensives (chapter 2) and. lipid-lowering drugs (chapter 3) are both drug
groups used in the treatment of cardi.ovascular risk factors, and are both hlpothesised
to prevent microalbuminuria,i-s either through their antihypertensive or lipid lowering
effect oÍ through some unknown mechanism. \X/e found that the various
antihypertensive drug groups had different impacts on urinary albumin cxcretion in
relation to blood pÍessure. These differences were in agreement with eadier findings.
ACE inhibitor use u'as associated with a lower urinary albumin excretion as related to
blood pressure.i-3'6 However, this was only seen when they were combined with
diuretics, suggesting ACE inhibitors ^te most effective i.n volume depleted
conditions.T Dihydropyridine calcium channel blockers on the c,ither hand, were thc
only antihlpertensive drug group to be associated with a higher prevalence of
microalbuminuria.l,2
Oral contraceptives,s,e hormone replacement therap)-,l0-I2 and corticosteroids
1l-15 are all known to have cardiovascular effects. How they influence the
cardiovascular system is not completely known, but it might be that urinary albumin
excretion is linked to this. If this is the case, mictoalbuminuria is a useful marker tc.r
inclicate subjects ^Í risk for catdiovascular side effects. And rndeed, with
microalbuminuria as a marker, we were able to illustrate known cardiovascular effects






















Summary and gcneral discussron
rlssociatjon with microalbuminuria, suggcsLilrg cardior.iiscular risk in stead of
pr()tecli()n, rvhich is irr irgrccrncnt s' ir[.r reccnt randomised cLinical tria]s.10 r2
Hrx.vcver, because of thc strong corÍelation of urinary nlbumin cxcre tion \\ ' i th
hl.pertension, dys[pidcmia, obesiq', ancl hyperglycaemia, iL pharmacoepidcmrological
investigation on associations betu'ecn drug usc ancl microalbuminuria is l-rampered bv
metl.rodokrgical pnrblems, thu nr()st impr)tt iult being confounding bl inclication. This
thesis tried to ar.oid tl-ris confouncling bv adjusung for cardiovascular isk factors rn
several wavs, but it is cluitc possible that sor.ne rcsidual cc;nfour-rcling is sti l l  pre sent.
Anothcr method()logical sl.rortcoming in this thesis is thzrt all investigation-s
werc cr()ss sectional. ,\ l though with using histolical pharmacv clatl i t kroks l ike a case-
control stuclt, all r 'ariablcs used tt,r acljust for confounding \\ 'erc measuÍed at the same
timc as the urinarv albur.nin cxcretion. I)ue to this cross-sectional natuÍc rt is hard, if
not impossiblc, to rnakc any collclusiol)s ()n cause ancl effcct. At prese nt, a
prospccur.c fir lkrlv-up of this cohort is unclcnval', with condnucs coilectit>n of
pharmacl' data and a second scrccninll oi the sr-rbjccts. \\ ' i th this íolkrw-up data it rvrl l
be possible to lnake more de trnitc conclr:sions. We can scc u.hcthcr drug use is indeed
capablc of causing or prcventing microalbuminuria, indcpendent of cardior.ascular risk
factors, bv looking at cl.rangcs in urinarv albumin excretion irr stead of onlv one
r-nensurcrricnt. Furtl-rermr)re, the influence of drug usc on renal tunction, dcfined as
eithcr a glomerular hvpertlltration or a dimmished filtration can Lre inr.estiElated rnore
thoroughlr'.
In conclusion manv drugs rvcre fcrurrd to be related to urinafl. albumin
excretiorr. Antihypertcnsive clrugs seem to bc able to l()wcr urinary albunrin cxcretjon,
rvhcreas \\''c \\'eÍc not able to fincl similar eftects frrr statins. Ilurtirermore, whcn
n-ricroalbuminuria consiclcred as an caÍl)- marker for increascd cardiovascular isk, it
can be a useful tool to detect subjccts at risk for carcliovascular aclvcrsc drug react.ions.
